Houston, United States
Research view
Chronic lymphocytic leukaemia: who works on it
Groups that published on this disease or run trials on it, from public registries and publications. Researchers appear by name only once their profile is published.
Find fellow researchers
One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.
- All targets
- BTK 26
- CD19 32
- BCL-2 10
- TP53 3
- CD20 10
- CD22 6
- ABL1 2
- PI3K 1
- NOTCH1 0
- CXCR4 0
- STAT3 0
- CD123 1
- CD38 1
- HMGB1 0
- PD-1 0
- PD-L1 0
- EGFR 0
- HDAC 0
- MDM2 0
- PPAR 0
- TIM-3 0
- AKT 0
- ALK 0
- ATM 0
- BCMA 1
- BDNF 0
- BRAF 0
- BRD4 0
- CD30 0
- CD47 0
- CSF1R 1
- CTNNB1 0
- ERK 0
- FAK 0
- FLT3 0
- IDH 0
- IL-23 0
- IL-4 0
- KMT2A 0
- MAPK 0
- MMP-9 0
- NRAS 0
- PCSK9 0
- PRMT5 0
- VEGF 0
EU-13 is a filter, not a ranking: it only narrows the list.
Rochester, United States
Boston, United States
Cambridge, United States
Milan, Italy
Milan, Italy
Basel, Switzerland
Cologne, Germany
Cologne, Germany
Seattle, United States
Philadelphia, United States
Brno, Czechia
Beijing, China
Columbus, United States
Seattle, United States
Padua, Italy
Tampa, United States
Boston, United States
Brno, Czechia
Melbourne, Australia
Jacksonville, United States
Indianapolis, United States
Duarte, United States
San Diego, United States
24 of 611 institutions, ordered by recent publications and open trials. This is not a ranking of quality.
Who stopped a trial, and why
Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.
Terminated
64Cu-LLP2A for Imaging Hematologic Malignancies
“Loss of further funding”Registry text, quoted unchanged. Source
Withdrawn
Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies
“No participants.”Registry text, quoted unchanged. Source
Suspended
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
“insufficient funding”Registry text, quoted unchanged. Source
Suspended
“Drugs unavailable”Registry text, quoted unchanged. Source
Terminated
A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies
“This decision is due to a company business decision with strategy change on the BGB-21447 development in B-cell malignancies and is not driven by safety concerns.”Registry text, quoted unchanged. Source
Terminated
“The study was terminated due to a strategic decision to discontinue development.”Registry text, quoted unchanged. Source
Terminated
“No longer a research question to answer.”Registry text, quoted unchanged. Source
Terminated
“Study was terminated prior to enrolling protocol target accrual goal due to declining accrual and Data Safety Monitoring Board recommendations.”Registry text, quoted unchanged. Source
Terminated
“Closed for administrative, non-safety-related reasons.”Registry text, quoted unchanged. Source
Suspended
Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors
“Because the implementation of the new regulation policy by the Chinese authority”Registry text, quoted unchanged. Source
Trials that share participant data
Trials whose registry record says individual participant data (IPD) will be shared.
Search by method
Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.
- Single-Cell Analysis 6
- Mendelian Randomization Analysis 2
- CRISPR-Cas Systems 1
- Gene Expression Profiling 9
- Sequence Analysis, RNA 1
- Whole Genome Sequencing 1
- Exome Sequencing 1
- Proteomics 2
- Metabolomics 1
- Mass Spectrometry 2
- Flow Cytometry 20
- Immunohistochemistry 6
- Circulating Tumor DNA 1
- Xenograft Model Antitumor Assays 9
- Magnetic Resonance Imaging 3
- Machine Learning 9
- Cohort Studies 18
- Genome-Wide Association Study 2
Paste an abstract
See which targets of this disease your abstract mentions, and go to the people working on them.
Matched in your browser only. The text is not sent, saved or logged.
Sources: ClinicalTrials.gov, EU CTR, OpenAlex, PubMed. Machine-matched links are labelled.